Research Analysts Issue Forecasts for Protara Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:TARA)

Protara Therapeutics, Inc. (NASDAQ:TARA) – Research analysts at HC Wainwright reduced their Q2 2024 EPS estimates for Protara Therapeutics in a research note issued to investors on Monday, May 6th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($1.09) per share for the quarter, down from their prior estimate of ($1.07). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q3 2024 earnings at ($1.14) EPS, Q4 2024 earnings at ($1.20) EPS, FY2024 earnings at ($4.40) EPS, FY2026 earnings at ($4.41) EPS, FY2027 earnings at ($3.35) EPS and FY2028 earnings at ($1.49) EPS.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.13.

Separately, Oppenheimer upped their price target on Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Monday, April 22nd.

Protara Therapeutics Stock Down 1.4 %

Shares of NASDAQ:TARA opened at $2.83 on Thursday. The company has a market cap of $32.35 million, a price-to-earnings ratio of -0.76 and a beta of 1.80. The business has a 50 day moving average price of $3.53 and a 200 day moving average price of $2.57. Protara Therapeutics has a twelve month low of $1.04 and a twelve month high of $5.24.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Protara Therapeutics stock. Oppenheimer & Co. Inc. purchased a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned approximately 0.09% of Protara Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.